Track market-moving stories before they get noisy

The stock’s decline comes amid a broader market rally, with major indices like the Nasdaq up by 1.19% and the S&P 500 gaining 0.72%.

• BioNTech stock is under selling pressure. What’s pulling BNTX shares down?

BioNTech Revenue Miss, Wider Net Loss Pressure SentimentIn its first-quarter financial results, BioNTech reported revenues of 118.1 million euros ($138 million), down from 182.8 million euros a year ago, missing the consensus estimate of $214.62 million.

The sales fell primarily due to lower sales of its COVID-19 vaccines.

The company also recorded a net loss of 531.9 million euros, compared to a net loss of 415.8 million euros in the prior year.

The COVID-19 vaccine maker reported an adjusted loss of 1.95 euros ($2.28), better than the Street’s loss expectation of $2.52.

“Our revenues for the first quarter reflect the seasonal demand for COVID-19 vaccines and are in line with our expectations,” said Ramón Zapata, CFO at BioNTech. “We are committed to a diligent capital allocation strategy that empowers us to pursue our goal of evolving into a leading biopharmaceutical company with multiple oncology products by 2030.”

Restructuring Plan Targets Cost Savings, Site ExitsBioNTech is planning to wind down operations at manufacturing sites in Idar-Oberstein, Marburg, Tübingen and Singapore, along with CureVac facilities, impacting up to 1,860 roles.

The exits from Idar-Oberstein, Marburg and Tübingen are targeted by end-2027, while Singapore operations are set to close in the first quarter of 2027. The company is evaluating divestment options for these sites, including partial or full sales.

The restructuring is expected to deliver phased cost savings, reaching roughly 500 million euros in recurring annual savings by 2029 at full run-rate.

BioNTech reiterated its FY2026 revenue guidance of 2 billion–2.3 billion euros ($2.33 billion–$2.68 billion), compared to the Wall Street estimate of $2.56 billion.

BNTX Stock Price Activity: BioNTech shares were down 3% at $96.37 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo: Piotr Swat / Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

By Reuters

May 6, 202611:44 AM UTCUpdated May 6, 2026

The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay/File Photo Purchase Licensing Rights, opens new tab

CompaniesBERLIN, May 6 (Reuters) - A German government ​spokesperson said on ‌Wednesday that the loss of ​BioNTech vaccine ​production in the country ⁠can be ​offset by other ​companies.

He added that the government continues ​to assume ​that the vaccine supply ‌to ⁠the population is guaranteed.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

BioNTech this week said it would ​close ​sites ⁠affecting up to 1,860 ​jobs, as ​the ⁠COVID-19 vaccine maker pivots ⁠away ​from pandemic-era ​manufacturing.

Reporting by Thomas Seythal Editing ​by Madeline Chambers

Our Standards: The Thomson Reuters Trust Principles., opens new tab

MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027. BioNTech’s disciplined approach to capital allocation and strong financial position enables this authorization.

BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The Program is designed to enhance capital efficiency, support long-term value creation and maintain financial flexibility alongside BioNTech’s objective to become a multi-product company by 2030.

The commencement, timing and total amount of ADS repurchases will depend upon market conditions and may be made in open market purchases from time to time, with a focus on price efficient repurchases to ensure prudent deployment of capital. BioNTech expects to fund the Program using its existing cash resources.

“We are confident in the Company’s long-term growth prospects, and this share repurchase program is consistent with our capital allocation strategy and our commitment to sustainable value creation for our shareholders,” said Ramón Zapata, Chief Financial Officer at BioNTech. “At the same time, our disciplined approach to capital deployment enables us to maintain the financial strength necessary to advance our innovative pipeline and aim for self-sustaining growth in the years ahead.”

The Program has been designed to operate within the safe harbor provided by Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the affirmative defense provided by Rule 10b5-1 of the Exchange Act.

About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the Company’s intent to repurchase, from time to time, the Company’s ADSs. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: changes in the market price of the Company’s ADSs, general market conditions and applicable securities laws.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. 

CONTACTS

Investor Relations
Douglas Maffei, PhD
[email protected]

Media Relations
Jasmina Alatovic
[email protected]

4 Reasons Pfizer Could Be a Value Play You Can't MissBioNTech NASDAQ: BNTX used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network.

Chairman of the Supervisory Board Helmut Jeggle said the 2025 fiscal year was “a successful one” for the company, citing progress toward BioNTech’s goal of becoming a multi-product company by 2030. He said the company ended 2025 with cash and marketable securities totaling EUR 17.2 billion, giving it “substantial resources” for its next phase of development.

Get BioNTech alerts:

Management Highlights Oncology Pipeline and BMS Partnership Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?Chief Executive Officer Professor Dr. Ugur Sahin, delivering what he described as his final annual general meeting address as CEO, said BioNTech’s strategy remains focused on two pillars: maintaining its COVID-19 vaccine business with partner Pfizer and using proceeds to advance a diversified development pipeline, particularly in oncology.

Sahin said BioNTech and Pfizer have delivered more than 5 billion COVID-19 vaccine doses worldwide since 2020. He added that BioNTech’s vaccine is distributed in more than 180 countries and regions and has a market share of more than 50% in key markets.

Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?In oncology, Sahin said BioNTech has more than 25 ongoing Phase 2 and Phase 3 studies, 17 clinical programs and a clinical evidence base that includes more than 4,000 patients. He said the company expects several data updates from key late-stage studies in 2026.

Sahin highlighted pumitamig, BioNTech’s next-generation bispecific immunomodulator, as the company’s “flagship program.” He said the candidate has shown anti-tumor activity across a broad range of cancers based on clinical data to date and may have potential as a combination partner with other agents.

BioNTech completed the acquisition of Biotheus in early 2025, bringing pumitamig fully into its pipeline, and in June 2025 entered into a global 50/50 development and commercialization collaboration with Bristol Myers Squibb. Sahin said the agreement includes a $1.5 billion upfront payment, $2 billion in additional unconditional payments and up to $7.6 billion in milestone payments.

Financial Outlook and Buyback Plan Chief Financial Officer Ramón Zapata said 2025 was a strong year for BioNTech, with total revenue of EUR 2.9 billion, slightly higher than the prior year despite lower COVID-19 vaccine revenue. The decline in vaccine revenue was partly offset by EUR 613 million recognized from the BMS collaboration.

Research and development expenses were about EUR 2.1 billion in 2025, slightly below the prior year, which Zapata attributed to portfolio management and cost sharing with BMS. For the first quarter of 2026, BioNTech reported revenue of EUR 118 million, compared with EUR 183 million a year earlier, reflecting lower COVID-19 vaccine demand. R&D expenses rose to EUR 557 million from EUR 526 million, while SG&A expenses increased to EUR 151 million from EUR 121 million.

BioNTech reaffirmed its 2026 guidance, expecting total revenue of EUR 2.0 billion to EUR 2.3 billion, adjusted R&D expenses of EUR 2.2 billion to EUR 2.5 billion and adjusted SG&A expenses of EUR 700 million to EUR 800 million.

Zapata also announced a share repurchase program of American Depositary Shares of up to $1 billion over the next 12 months. He said the program reflects “confidence in our science, capital management discipline, and a commitment to delivering long-term value for our shareholders.”

Manufacturing Consolidation to Affect About 1,800 Employees BioNTech executives also addressed the company’s planned manufacturing consolidation. Zapata said BioNTech identified sites where capacity is expected to become significantly underutilized or idle over the next 24 months and decided to exit operations at sites in Idar-Oberstein, Marburg and Singapore, as well as CureVac sites.

The decision affects approximately 1,800 colleagues, Zapata said. He added that BioNTech is exploring divestment options, including partial or full sales of the sites, and expects recurring annual savings could reach about EUR 500 million by 2029, excluding exit costs.

Sahin said the decisions were made “with a heavy heart” and after careful analysis. He said the company intends to seek socially responsible solutions for affected employees and is working with policymakers, scientific institutions and regional partners.

Zapata said commercial and clinical drug supply will not be affected. Future clinical manufacturing for mRNA-based candidates will be covered by BioNTech’s broader network, including Mainz, while commercial COVID-19 vaccine production will be handled by Pfizer from the end of 2026.

Leadership Changes and New Company Plans Jeggle said Jens Holstein retired as planned as chief financial officer on June 30, 2025, and was succeeded by Zapata on July 1. Ryan Richardson, former chief strategy officer, stepped down from the Management Board by mutual agreement effective Sept. 30, 2025. The Supervisory Board also extended the appointment of Chief Operating Officer Sierk Pötting through Dec. 31, 2027.

Kylie Jimenez, appointed chief human resources officer effective March 1, 2026, told shareholders that her role is to help BioNTech’s organization, leadership and talent evolve with its strategy as it builds toward becoming a global multi-product commercial biotechnology company.

Jeggle also addressed the previously announced departures of Sahin and Chief Medical Officer Professor Dr. Özlem Türeci, who are set to leave BioNTech at the end of the year after founding and building the company over 18 years. He said they plan to focus on a new company dedicated to next-generation mRNA candidates. In response to submitted shareholder questions, Jeggle said BioNTech’s intellectual property rights, including patents, trademarks and technology platforms, are assets of the BioNTech Group and do not belong personally to the co-founders.

Shareholders Approve AGM Resolutions Shareholders representing 92% of BioNTech’s registered share capital were present or represented at the meeting. No live shareholder questions were submitted during the general debate.

All management and Supervisory Board proposals on the agenda were approved by the required majorities. These included carrying forward the 2025 balance sheet profit, approving the compensation report, expanding the Supervisory Board from six to eight members, electing Supervisory Board members, renewing authorization for virtual annual general meetings, creating a new authorized capital 2026 and approving a domination and profit and loss transfer agreement between BioNTech SE and BioNTech Discovery GmbH.

About BioNTech NASDAQ: BNTXBioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in BioNTech Right Now?Before you consider BioNTech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.

While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapyGotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment optionContinued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart. In addition, four trial in progress poster presentations will illustrate advancement of the Company’s ongoing pivotal trials and novel-novel combination trials, including antibody-drug conjugates (“ADC”).

“Achieving more for patients with cancer through translating science into innovative therapies is our unwavering ambition at BioNTech,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “At this year’s ASCO, our presentations underscore our oncology strategy of building a diversified portfolio of complementary modalities delivering differentiated therapeutic profiles across tumor types with high unmet medical need. We are focused on accelerating key strategic programs, both as monotherapies and combinations with standard of care treatments, to deliver our first wave of oncology innovations to patients. Simultaneously, and building on this momentum, we are advancing novel-novel combination approaches, including ADC-based regimens, to unlock the full synergistic potential of our pipeline.”

Highlights of BioNTech’s late-stage oncology programs to be presented at ASCO 2026:
Pumitamig (BNT327/BMS986545) – an investigational bispecific immunomodulator combining PD-L1 checkpoint inhibition and VEGF-A neutralization, developed in collaboration with Bristol Myers Squibb Company (“BMS”):

1L NSCLC: Data from the interim analysis of the Phase 2 dose-optimization part of the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) showed encouraging anti-tumor activity in first-line (“1L”) non-small cell lung cancer (“NSCLC”). The trial evaluated pumitamig plus chemotherapy in patients with non-squamous and squamous NSCLC without actionable genomic alterations and across PD-L1 expression levels. These data mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig plus chemotherapy, adding to the reported global data in small cell lung cancer and triple-negative breast cancer. The results inform the ongoing pivotal Phase 3 part of ROSETTA Lung-02 evaluating pumitamig plus chemotherapy versus pembrolizumab plus chemotherapy. Updated data from a later cut-off date will be presented in a rapid oral presentation. Gotistobart (BNT316/ONC-392) – an investigational tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4, developed in collaboration with OncoC4, Inc. (“OncoC4”):

PROC: Data from the Phase 2 PRESERVE-004 clinical trial (NCT05446298) evaluating gotistobart plus pembrolizumab in heavily pre-treated patients with platinum-resistant ovarian cancer (“PROC”) showed durable anti-tumor activity and clinically meaningful overall survival outcomes. Together with a manageable safety profile, the results add to the growing body of evidence supporting gotistobart’s potential as a chemotherapy-free treatment option, complementing the recently announced data in second and later line squamous non-small cell lung cancer.
BioNTech is advancing a diversified oncology pipeline spanning next-generation immunomodulators, ADCs, and mRNA cancer immunotherapies, both as monotherapies and novel treatment combination approaches. With more than 25 Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials, BioNTech is focused on developing innovative approaches to address the challenges of cancer treatment among the Company’s tumor focus areas from early to late-stage conditions.

All abstracts are available on the ASCO website. Further information on BioNTech’s late-stage oncology portfolio can be accessed here.

Full presentation details:

MedicineAbstract TitleAbstract Number/Presentation DetailsPumitamigPhase 2 data from ROSETTA Lung-02, a global randomized Phase 2/3 trial of pumitamig (PDL1 × VEGF-A bsAb) + chemotherapy in 1L NSCLCAbstract #8513
Rapid Oral Abstract Session
Lung Cancer - Non-Small Cell Metastatic
May 30, 2026, 1:15 - 2:45pm CDTPhase 2/3 trial of pumitamig (PD-L1 ×VEGF-A bsab) plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated, unresectable, or metastatic colorectal cancer (ROSETTA CRC-203)Abstract #TPS3672
Poster Session
Genitourinary Cancer - Prostate, Testicular, and Penile
Poster Board: 229a
May 31, 2026: 9:00am-12:00pm CDTGotistobartOverall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumabAbstract #5511
Rapid Oral Abstract session
Gynecologic Cancer
May 30, 2026: 8:00 - 9:30am CDTBNT326/YL202BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumorsAbstract #TPS3160
Poster Session
Developmental Therapeutics -Molecularly Targeted Agents and Tumor Biology
Poster Board: 294b
May 30, 2026: 1:30 - 4:30pm CDTBNT324/DB-1311BNT324-03: A Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC)Abstract #TPS5137
Poster Session
Genitourinary Cancer - Prostate, Testicular, and Penile 
Poster Board: 229a
May 31, 2026: 9:00am - 12:00pm CDTTrastuzumab pamirtecan 
(BNT323/DB-1303)Fern-EC-01 (BNT323-01): A phase 3 trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in patients with previously treated, HER2-expressing, recurrent endometrial cancer (EC)Abstract #TPS5645
Poster Session
Gynecologic Cancer
Poster Board: 302b
June 1, 2026: 9:00am - 12:00pm CDT About BioNTech

BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

  

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the initiation, timing, progress and results of BioNTech’s research and development programs in oncology, including the targeted timing and number of additional potentially registrational trials; BioNTech’s and its collaborators’ current and future preclinical and clinical trials in oncology, including the investigational bispecific immunomodulator pumitamig (BNT327/BMS986545) in multiple indications, the investigational anti-CTLA-4 antibody gotistobart (BNT316/ONC-392) in multiple indications, the investigational B7H3-targeted ADC BNT324/DB-1311 in metastatic castration-resistant prostate cancer, the investigational HER2-targeted ADC trastuzumab pamirtecan (BNT323/DB-1303) in recurrent endometrial cancer, and the investigational HER3-targeted ADC BNT326/YL202 as monotherapy and in combination with pumitamig in NSCLC and advanced solid tumors; the nature and characterization of and timing for release of clinical data across BioNTech’s platforms, which is subject to peer review, regulatory review and market interpretation; the planned next steps in BioNTech’s pipeline programs, including, but not limited to, statements regarding timing or plans for initiation or enrollment of clinical trials, or submission for and receipt of product approvals and potential commercialization with respect to BioNTech’s product candidates; the ability of BioNTech’s mRNA technology to demonstrate clinical efficacy outside of BioNTech’s infectious disease platform; and the potential safety and efficacy of BioNTech’s product candidates. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the ability to produce comparable clinical results in future clinical trials; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; discussions with regulatory agencies regarding timing and requirements for additional clinical trials; BioNTech’s and its counterparties’ ability to manage and source necessary energy resources; the impact of tariffs and escalations in trade policy; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

Media Relations
Jasmina Alatovic
[email protected]

Investor Relations
Douglas Maffei, PhD
[email protected]

Key Takeaways BMY's phase III SUCCESSOR-2 study showed mezigdomide cut progression or death risk by 52% in RRMM.BMY reported higher response rates for MeziKd, with 80.2% overall and 26.7% complete responses.BMY and BioNTech shared phase II pumitamig data showing strong first-line NSCLC activity. Bristol Myers Squibb (BMY - Free Report) reported phase III SUCCESSOR-2 results of CELMoD (cereblon E3 ligase modulation) mezigdomide.

These results were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

SUCCESSOR-2 is an inferential, seamless phase II/III, multicenter, randomized, open-label study evaluating the efficacy and safety of mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM).

Mezigdomide is an oral CELMoD therapy developed using BMY’s targeted protein degradation platform.

More on BMY’s SUCCESSOR-2 ResultsResults showed MeziKd demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS), representing a 52% reduction in the risk of disease progression or death compared with Kd.

The data revealed significant PFS benefits observed across both second- and third-line patients, including those with high-risk disease. The MeziKd regimen delivered markedly higher response rates, with an overall response rate of 80.2% versus 53.4% and complete response rates of 26.7% versus 8.9% for the control arm. Median overall survival has not yet been reached.

While the safety profile was consistent with prior experience, higher rates of Grade 3-4 adverse events, particularly neutropenia and infections, were reported.

BMY plans to share the results with health authorities.

BMY and Partner BNTX Present Data on PumitamigBMY and partner BioNTech (BNTX - Free Report) reported encouraging interim phase II results from the ROSETTA Lung-02 study evaluating pumitamig (BNT327/BMS-986545) plus chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC) at the ASCO.

Pumitamig is an investigational bispecific immunomodulator, jointly developed by BNTX and BMY, designed to cooperatively bind to PD-L1 and VEGF-A.

The phase II part of the ROSETTA Lung-02 study evaluated pumitamig in two dose levels, in combination with chemotherapy.

The investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line NSCLC at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes.

Pumitamig plus chemotherapy demonstrated a manageable safety profile with a low discontinuation rate.

BioNTech and BMY are pursuing an extensive development strategy for pumitamig across multiple NSCLC settings. In addition to the ongoing global ROSETTA Lung-02 study, which is currently recruiting for the phase III part of the study, two additional global phase III studies are actively enrolling, targeting both unresectable stage III disease and first-line PD-L1–high advanced NSCLC. The broad clinical program, coupled with ongoing combination studies involving antibody-drug conjugates and other novel therapies, highlights pumitamig’s potential to become a major oncology franchise and a significant long-term value driver for both companies.

BMY Advancing a Promising Pipeline to Drive GrowthWe note that BMY boasts a deep and promising pipeline. Key pipeline candidates with multi-billion-dollar potential are milvexian (Oral factor XIa inhibitor), admilparant (LPA1 antagonist), pumitamig (PD-L1 x VEGF-A bispecific antibody) and iberdomide & mezigdomide (oral CELMoD protein degraders).

The company’s targeted protein degradation platform — built over two decades — also includes investigational approaches such as ligand-directed degraders and degrader antibody conjugates. These programs aim to tackle disease-driving proteins that were previously considered difficult to target with traditional drugs.

The FDA has accepted a new drug application for iberdomide in combination with standard treatment (daratumumab and dexamethasone) for RRMM, granting Breakthrough Therapy Designation and Priority Review, with a target action date of Aug. 17, 2026.

The company, in partnership with Johnson & Johnson, is developing milvexian for atrial fibrillation (AF) and secondary stroke prevention (SSP).

Shares of the company have gained 6% year to date compared with the industry’s growth of 0.3%.

Image Source: Zacks Investment Research

Concurrent with the first-quarter results reported in April, BMY highlighted the growing depth and diversification of its pipeline, with several pivotal phase III readouts expected in the second half of 2026, including milvexian in AF and SSP, Cobenfy in Alzheimer's disease psychosis, and iberdomide PFS data. Positive outcomes from these programs could further de-risk the company's long-term growth outlook, expand its portfolio, and support its goal of launching more than 10 new drugs and 30 lifecycle expansion opportunities by the end of the decade.

Management also emphasized ongoing efforts to improve R&D productivity, streamline clinical development, and strengthen the early and mid-stage pipeline, positioning the company for sustained innovation and future revenue growth as its legacy portfolio continues to be adversely impacted by the continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane.

BMY’s Zacks Rank & Key PicksBMY currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have gained 79.4% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 30 days, estimates for Immunocore’s 2026 loss per share have narrowed from a loss of 88 cents to earnings of 6 cents. Over the same period, earnings estimates for 2027 have increased to 87 cents per share from 24 cents per share. IMCR shares have lost 16.8% year to date.

Shares of Cenovus Energy (CVE - Free Report) have been strong performers lately, with the stock up 26.7% over the past month. The stock hit a new 52-week high of $31.68 in the previous session. Cenovus has gained 86.6% since the start of the year compared to the 32% gain for the Zacks Oils-Energy sector and the 68.1% return for the Zacks Oil and Gas - Integrated - Canadian industry.

What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on May 6, 2026, Cenovus reported EPS of $0.61 versus consensus estimate of $0.56 while it missed the consensus revenue estimate by 2.75%.

For the current fiscal year, Cenovus is expected to post earnings of $3.01 per share on $37.4 in revenues. This represents a 95.45% change in EPS on a 5.19% change in revenues. For the next fiscal year, the company is expected to earn $2.76 per share on $38.04 in revenues. This represents a year-over-year change of -8.42% and 1.7%, respectively.

Valuation MetricsWhile Cenovus has moved to its 52-week high in the recent past, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.

On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.

Cenovus has a Value Score of B. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of B.

In terms of its value breakdown, the stock currently trades at 10.5X current fiscal year EPS estimates, which is not in-line with the peer industry average of 12.2X. On a trailing cash flow basis, the stock currently trades at 9.1X versus its peer group's average of 11.2X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.

Zacks RankWe also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, Cenovus currently has a Zacks Rank of #1 (Strong Buy) thanks to favorable earnings estimate revisions from covering analysts.

Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Cenovus fits the bill. Thus, it seems as though Cenovus shares could have a bit more room to run in the near term.

Key Takeaways Cenovus expects upstream production to exceed 1.1 MMBoe/d by 2028.CVE plans to increase oil sands output from Christina Lake, Foster Creek and Sunrise projects.Cenovus expects West White Rose to reach peak production of 45 Mbbls/d by 2028. Cenovus Energy Inc. (CVE - Free Report) is a Canadian energy company that develops, produces, refines, and markets crude oil, natural gas and petroleum products across North America and the Asia-Pacific region. With a diversified upstream portfolio spanning oil sands, offshore, thermal heavy oil and conventional assets, CVE is positioned to meet rising global hydrocarbon demand. The company projects total upstream production to grow from approximately 965 thousand barrels of oil equivalent per day (MBoe/d) in 2026 to more than 1.1 million barrels of oil equivalent per day (MMBoe/d) by 2028.

By 2028, Cenovus aims to significantly boost its oil sands output through several high-impact projects. Christina Lake North is expected to add about 40 thousand barrels per day (Mbbls/d) of production by 2028 through redevelopment wells and new steam generators. Foster Creek is projected to contribute additional output, while Sunrise production is expected to rise by 15-20 Mbbls/d between 2024 and 2028. In the Lloydminster region, Cenovus expects thermal and conventional heavy oil projects to add around 30 Mbbls/d combined by 2028. 

The West White Rose offshore project is on track to achieve first production in 2026 and reach peak output of roughly 45 Mbbls/d by 2028. By merging offshore capabilities with its conventional and long-life oil sands assets, the company has built a balanced portfolio. This strategic mix positions the company well to support rising global hydrocarbon demand.

Can FANG & XOM Increase Output Through Diversified Portfolios?Diamondback Energy, Inc. (FANG - Free Report) is a leading Permian-focused independent oil and gas producer with 890,496 net acres across the Permian Basin, including 797,074 net acres in the Midland Basin and 93,422 net acres in the Delaware Basin. The company develops stacked resources in the Spraberry, Wolfcamp and Bone Spring formations using advanced horizontal drilling and high-intensity completion techniques. Supported by strong operational execution and efficiency gains, FANG raised its 2026 oil production outlook to more than 520 thousand barrels of oil per day (MBO/d) from the prior range of 500-510 MBO/d, while total production guidance has been raised to more than 972 MBoe/d from the prior range of 926-962 MBoe/d.

Exxon Mobil Corporation (XOM - Free Report) drives its growth through a geographically diversified portfolio anchored by the Permian Basin, offshore Guyana and its liquified natural gas (LNG) operations. In the first quarter of 2026, XOM achieved its first LNG production at Golden Pass Train 1, a milestone projected to boost U.S. LNG exports by 5% compared with 2025. ExxonMobil’s Permian production is on track to reach about 1.8 million barrels of oil equivalent (MMBoe/d) in 2026, paving the way for a 2.5 MMBoe/d long-term Permian production goal and 5.5 MMBoe/d total upstream output by 2030.

CVE’s Price Performance, Valuation & EstimatesCenovus shares have gained 120.4% over the past year compared with 97.3% growth of the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, CVE trades at a trailing 12-month enterprise-value-to-EBITDA (EV/EBITDA) of 7.4X. This is below the broader industry average of 7.84X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for CVE's first-quarter 2026 earnings has seen upward revisions over the past seven days. Meanwhile, estimates for second-quarter 2026 and full-year 2026 earnings have remained constant.

Image Source: Zacks Investment Research

CVE currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

CVE's integration and MEG's Christina Lake North face off against COP's unhedged upstream bet as oil prices rise.

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.

In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.

However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.

Our proprietary system currently recommends Cenovus Energy (CVE - Free Report) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.

Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.

While there are numerous reasons why the stock of this oil company is a great growth pick right now, we have highlighted three of the most important factors below:

Earnings GrowthArguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Cenovus is 22.5%, investors should actually focus on the projected growth. The company's EPS is expected to grow 104.8% this year, crushing the industry average, which calls for EPS growth of 87.7%.

Cash Flow GrowthWhile cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.

Right now, year-over-year cash flow growth for Cenovus is 11.6%, which is higher than many of its peers. In fact, the rate compares to the industry average of 3.8%.

While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 59% over the past 3-5 years versus the industry average of 16%.

Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The current-year earnings estimates for Cenovus have been revising upward. The Zacks Consensus Estimate for the current year has surged 38.1% over the past month.

Bottom LineCenovus has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #1 because of the positive earnings estimate revisions.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

This combination indicates that Cenovus is a potential outperformer and a solid choice for growth investors.

The broader equity markets witnessed intense volatility over the past week, hitting record highs on one hand and plummeting sharply on the other, as skirmishes in the Iran-U.S. war continued with a fragile ceasefire agreement. As oil prices swung across the fulcrum, bond yields soared, and equity markets took a hammering amid concerns over rising inflation. However, the markets were quick to bounce back as investors appeared to rotate out of chip names in favor of non-tech stocks despite an AI-infused inherent market strength.

The persistent Iran blockade and restrictions in the Strait of Hormuz continue to add to the stock market misery, with uncertainty being the order of the day. As investors employ a wait-and-see approach in a classic example of “backing and filling” in the market, they can benefit from “cash cow” stocks that garner higher returns. However, identifying cash-rich stocks alone does not make for a solid investment proposition unless it is backed by attractive efficiency ratios, such as return on equity (ROE). A high ROE ensures that the company is reinvesting cash at a high rate of return. Ross Stores, Inc. (ROST - Free Report) , TE Connectivity plc (TEL - Free Report) , Cenovus Energy Inc. (CVE - Free Report) , Globe Life Inc. (GL - Free Report) and The Charles Schwab Corporation (SCHW - Free Report) are some of the stocks with high ROE to profit from.

In order to shortlist stocks that are cash-rich with high ROE, we have added Cash Flow greater than $1 billion and ROE greater than X-Industry as our primary screening parameters. In addition, we have taken a few other criteria into consideration to arrive at a winning strategy.

Price/Cash Flow less than X-Industry: This metric measures how much investors pay for $1 of free cash flow. A lower ratio indicates that investors need to pay less for a better cash flow-generating stock.

Return on Assets (ROA) greater than X-Industry: This metric determines how much profit a company earns for every dollar of assets, which includes cash, accounts receivable, property, equipment, inventory and furniture. The higher the ROA, the better it is for the company.

5-Year EPS Historical Growth greater than X-Industry: This criterion indicates that continued earnings momentum has translated into solid cash strength.

Zacks Rank less than or equal to 2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.

Here are five of the 14 stocks that qualified the screening:

Ross: Based in Dublin, CA, Ross is an off-price retailer of apparel and home accessories, offering in-season, branded and designer apparel, footwear, accessories and other home-related merchandise. Operating primarily in the United States, it targets middle-income households, keeping prices at generally 20% to 60% below the regular prices of most department and specialty stores.

The company has a long-term earnings growth expectation of 11.5% and delivered a trailing four-quarter earnings surprise of 10.2%, on average. Ross carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

TE Connectivity: Based in Galway, Ireland, TE Connectivity is a global technology company that designs and manufactures connectivity and sensor solutions for a wide range of industries, including automotive, aerospace, defense, energy and medical. With operations in more than 130 countries, TE Connectivity focuses on emerging technologies such as 5G, electric vehicles, industrial automation and smart cities to position itself at the forefront of connectivity advancements.

The company has a long-term earnings growth expectation of 12.5%. It delivered a trailing four-quarter earnings surprise of 6%, on average. It has a VGM Score of B. TE Connectivity carries a Zacks Rank #2.

Cenovus Energy: Calgary, Canada-based Cenovus Energy is a leading integrated energy firm. Starting from pumping out oil from its oil sands projects in Canada, the company’s operations comprise marketing the produced oil, natural gas and natural gas liquids. CVE supplies oil to the Gulf Coast of the United States through the Enbridge Flanagan South pipeline.

It has a VGM Score of A and delivered a trailing four-quarter earnings surprise of 50.8%, on average. Cenovus Energy currently sports a Zacks Rank #1.

Globe Life: Based in McKinney, TX, Globe Life is an insurance holding company that markets primarily individual life and supplemental health insurance to lower-middle to middle-income households throughout the United States. The company's insurance subsidiaries write a variety of non-participating ordinary life insurance products, which include traditional whole life, term life and other life insurance. Globe Life offers Medicare Supplement and limited-benefit supplemental health insurance products that include primarily critical illness and accident plans.

It delivered a trailing four-quarter earnings surprise of 1.1%, on average. Globe Life carries a Zacks Rank #2 at present.

Charles Schwab: Headquartered in Westlake, TX, The Charles Schwab Corporation is a savings and loan holding company that provides wealth management, securities brokerage, banking, asset management, custody and financial advisory services. The company has nearly 400 branches across 48 states and the District of Columbia, as well as locations in Puerto Rico, the U.K., Hong Kong and Singapore.

The company has a long-term earnings growth expectation of 17.3%. It delivered a trailing four-quarter earnings surprise of 3.8%, on average. Charles Schwab carries a Zacks Rank #2.

Key Takeaways Cenovus' heavy oil production is tied to WCS, which typically trades below WTI prices.CVE expects more than 750 MBbls/D of heavy oil egress and conversion capacity by 2028.CVE uses pipeline access and refining assets to boost margins and support cash flows. Cenovus Energy Inc. (CVE - Free Report) is a Canadian integrated energy company with operations spanning the upstream and downstream sectors. While Cenovus benefits from the low-cost and long reserve life of its asset base, its upstream business could be affected by price volatility in global markets. Crude prices fluctuate heavily due to several factors, including supply-demand dynamics, geopolitical factors and more. Cenovus’ production primarily comes from its Canadian oil sands assets, which consist of heavy and bitumen-blend crude linked to the Western Canadian Select (“WCS”) pricing. WCS usually trades at a discount compared to the West Texas Intermediate (“WTI”) benchmark.

However, the company’s access to pipeline capacity and its downstream infrastructure provides a cushion against the risk of Canadian heavy oil price dislocations. Notably, the company has stated that it expects to have more than 750 thousand barrels per day (MBbls/D) of heavy oil egress and conversion capacity by 2028, supported by its Canadian and U.S. refining capacity, TMX access and future contracted U.S. pipeline capacity.

Access to midstream infrastructure allows CVE to move its heavy oil production to markets that support better pricing. Additionally, the strong reliability of its Canadian and U.S. refining operations enables it to process and upgrade the discounted heavy crude into higher-value refined products, including diesel and jet fuel. The integrated nature of the business allows CVE to capture higher margins across the value chain, from production to finished products. Cenovus is well-positioned to withstand pricing dislocations while preserving cash flows and maintaining profitability.

Other Canadian Integrated Energy CompaniesCanadian Natural Resources (CNQ - Free Report)  is one of the largest independent energy companies in Canada, engaged in the exploration, development and production of oil and natural gas. The company boasts a diversified portfolio of crude oil, natural gas, bitumen and synthetic crude oil. Canadian Natural has set an ambitious production target for 2026, aiming for a total annual production range of 1,615 thousand barrels of oil equivalent per day (MBOE/d) to 1,665 MBOE/d. This target represents an approximately 4% increase in production compared with 2025.

Imperial Oil Limited (IMO - Free Report) is another leading integrated energy company headquartered in Canada. IMO’s operations span exploration and production, refining and a petrochemicals business. The company is a major Canadian oil sands producer and the largest jet fuel supplier in the country. Notably, the U.S. oil giant Exxon Mobil holds an approximately 71% stake in the Canadian operator.

CVE’s Price Performance, Valuation & EstimatesShares of CVE have jumped 118.5% over the past year compared with the 92.5% improvement of the composite stocks belonging to the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, CVE trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 7.35X. This is above the broader industry average of 7.7X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for CVE’s 2026 earnings hasn’t seen any revisions over the past seven days.

Image Source: Zacks Investment Research

CVE and IMO currently sport a Zacks Rank #1 (Strong Buy) each, while CNQ carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Key Takeaways CVE shares skyrocketed 109.2% in a year, outpacing CNQ, SU and the sub-industry's 79.1% surge.CVE's MEG deal adds oil sands assets; the 2026 synergy target is now expected to top C$150M.CVE growth projects are advancing, with Narrows Lake above 65,000 bpd and more due in 2026. Over the past year, Cenovus Energy Inc. (CVE - Free Report) shares have skyrocketed 109.2%, significantly outperforming Canadian Natural Resources Limited's (CNQ - Free Report) 46.4% gain and Suncor Energy's (SU - Free Report) 71% surge. During the same period, the stock has surpassed the sub-industry’s 79.1% rally. The company has emerged as one of the strongest energy players.

Image Source: Zacks Investment Research

The company's systematic strategic planning, expanding production profile and productive acquisition integration have strengthened its position within the Canadian energy space. As CVE approaches a potential turning point, investors are increasingly assessing whether the stock can continue its upward trajectory based on its underlying fundamentals.

To answer that question, it is important to look beyond the recent share price appreciation and evaluate the operating drivers supporting Cenovus' momentum.

Further reinforcing investor confidence, CVE has surpassed the Zacks Consensus Estimate in the past four quarters, delivering an average earnings surprise of 50.8%. In a sector often characterized by commodity-driven volatility, that level of earnings consistency stands out.

Image Source: Zacks Investment Research

Key Drivers Supporting CVE StockSuccessful Integration of MEG Energy Acquisition: One of Cenovus’ major recent catalysts has been the successful integration of the MEG Energy acquisition, completed in late 2025 for C$7.1 billion. The transaction added strategically valuable oil sand assets adjacent to Cenovus' Christina Lake operations.

The company noted that redevelopment wells at Christina Lake North are already outperforming original expectations. As a result, Cenovus expects to exceed its initial 2026 synergy target of C$150 million and continues to project annual synergies of more than C$400 million by 2028.

The acquisition significantly enhances the company's long-term outlook by lowering production costs and expanding production capacity. It also strengthens Cenovus' reserve base and further solidifies its position among Canada's leading oil sand producers.

Strong Progress on Growth Projects: Several major growth projects continued to advance in the first quarter of 2026. At Narrows Lake, production exceeded 65,000 barrels per day from the first four well pads, outperforming internal expectations. Cenovus expects output to increase to 80,000 barrels per day later in 2026.

The company also completed construction and commissioning activities at the West White Rose Project and commenced offshore drilling operations. First oil is expected in the third quarter of 2026, reaching a milestone for the development.

Cenovus continues to advance several growth initiatives, including the Christina Lake North expansion, Sunrise optimization, Foster Creek optimization and West White Rose projects. These developments support management's objective of exceeding 1 million BOE/d of upstream production by 2028.

Higher Oil Prices Could Boost Cenovus' Cash Flow Generation: Recent trends in crude markets have become increasingly favorable for upstream energy producers. WTI crude has recently traded near the $90-per-barrel level, well above the year-ago levels.

Cenovus' production portfolio consists largely of heavy and bitumen-blend crude sourced from Canada's oil sands. While its realized pricing remains tied to Western Canadian Select (“WCS”), which typically trades at a discount to WTI due to quality and transportation factors, higher benchmark oil prices generally support stronger realized WCS pricing. As a result, a sustained period of elevated crude prices could improve upstream netbacks, strengthen free cash flow generation and enhance financial flexibility.

In addition, Cenovus' integrated business model provides diversification through its downstream refining operations, helping balance performance across different commodity market environments.

Estimate Revisions & ValuationsOver the past 30 days, analyst sentiment toward Cenovus has improved. The Zacks Consensus Estimate for the company's earnings per share has moved higher for 2026 and 2027, reflecting growing confidence in its operational outlook and earnings potential.

Image Source: Zacks Investment Research

From a valuation standpoint, Cenovus continues to trade at attractive levels relative to the industry and key peers. CVE currently carries a trailing 12-month EV/EBITDA multiple of 7.11X, modestly below the broader industry average of 7.34X.

The stock also trades at a significant discount to Canadian Natural Resources, which currently commands an EV/EBITDA multiple of 9.86X. While Suncor Energy trades at 6.66X, Cenovus offers a stronger growth profile, supported by acquisition synergies, expanding production and multiple development projects nearing completion.

Image Source: Zacks Investment Research

Should Investors Consider CVE Stock Now?Cenovus appears well-positioned to deliver long-term value through a combination of strong operational execution, visible production growth and improving cash flow generation. The successful integration of MEG Energy, steady progress across major development projects and favorable commodity pricing collectively strengthen the company's earnings outlook.

The Zacks Rank #1 (Strong Buy) stock continues to trade at a valuation discount relative to the broader industry and certain key peers. As a result, investors may want to consider buying CVE at the current levels. The stock offers exposure to a high-quality Canadian energy producer with multiple growth catalysts while still trading at an attractive valuation.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Key Takeaways CVE increased its quarterly base dividend by 10% to 22 cents per share, marking six straight years of growth.Cenovus returned $1.0B to its shareholders through buybacks, dividends and redemptions in Q1 2026.CVE's key projects are expected to enhance its production, cash flow and future shareholder returns. Cenovus Energy Inc. (CVE - Free Report) is a leading Canadian integrated energy company with a diversified asset portfolio spanning oil sands, conventional oil and gas assets, offshore operations and refining facilities across Canada and the United States. CVE’s upstream operations generate the majority of its revenues by extracting crude oil, natural gas liquids and natural gas. The integrated giant’s downstream business generates revenues by refining these resources into petroleum products like gasoline and diesel.

Cenovus generates enough revenues to return capital to its shareholders through dividends and share buybacks. In the first quarter of 2026, CVE increased its quarterly base dividend by 10% to 22 cents per share, marking six consecutive years of dividend growth. During the same period, the company returned approximately $1.0 billion to its shareholders through dividends, share buybacks and preferred share redemptions. Since 2021, Cenovus has repurchased about 13% of its outstanding shares.

Cenovus plans to boost its future cash flows through several high-return growth projects. Key initiatives include the Christina Lake North expansion, the West White Rose offshore project, the Foster Creek optimization project and the Sunrise expansion. These projects are expected to boost production, cash flow and shareholder returns over the long term.

XOM & CVX Focus on Returning Capital to Its ShareholdersExxon Mobil Corporation (XOM - Free Report) and Chevron Corporation (CVX - Free Report) are other integrated giants that generate enough revenues to return capital to their shareholders.

ExxonMobil distributed $9.2 billion to shareholders, including $4.3 billion in dividends and $4.9 billion through stock repurchases. This strong capital return program keeps XOM on pace with its plan to repurchase $20 billion of shares in 2026.

Chevron rewarded shareholders with a total of $27.1 billion through 2025, including $12.1 billion in share repurchases and $2.2 billion related to the acquisitions of Hess Corporation. This strong shareholder return program marked the company's 38th consecutive year of annual dividend increases. Continuing this trend into early 2026, CVX paid out $3.5 billion in common stock dividends and repurchased $2.5 billion worth of shares during the first quarter.

CVE’s Price Performance, Valuation & EstimatesCenovus shares have gained 96.7% over the past year compared with 66.7% growth of the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, CVE trades at a trailing 12-month enterprise-value-to-EBITDA (EV/EBITDA) of 7.03X. This is below the broader industry average of 7.21X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for CVE’s 2026 earnings has remained constant over the past seven days.

Image Source: Zacks Investment Research

CVE currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jefferies Financial Group Inc. (“Jefferies” or the “Company”) (NYSE: JEF).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Jefferies and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, The Wall Street Journal published an article entitled “Auto Supplier First Brands Files for Bankruptcy Amid Accounting Questions,” reporting that “[t]he closely held company’s lenders and independent board directors are now probing whether First Brands made misrepresentations in its financial reporting” and that “First Brands relied heavily on accounts-receivable-backed financing, supplying automotive products to customers on delayed payment terms and borrowing from outside investors against the billed receivables.”  Then, on October 8, 2025, The Wall Street Journal further reported, in an article entitled “First Brands Bankruptcy Damage Spreads to Jefferies UBS,” that Jefferies “said funds run by an asset-management unit, Point Bonita Capital, are owed around $715 million from companies that bought First Brands’ parts.”  

On this news, Jefferies’ stock price fell $4.66 per share, or 7.88%, to close at $54.44 per share on October 8, 2025. 

The following day, Reuters disclosed that “The U.S. Department of Justice has launched an inquiry into the collapse of bankrupt auto parts maker First Brands Group” and that “[t]he Justice Department is probing the company and its dealings with creditors.” 

On this news, Jefferies’ stock price fell another $1.43 per share, or 2.63%, to close at $53.01 per share on October 9, 2025. 

On November 27, 2025, The Financial Times reported that the U.S. Securities and Exchange Commission is investigating Jefferies in connection with its relationship with First Brands, including whether Jefferies gave investors in its Point Bonita fund enough information about their exposure to First Brands.  Later, on January 7, 2026, The Financial Times reported that Jefferies took a $30 million loss tied to the collapse of First Brands.  

On this news, Jefferies’ stock price fell $3.62 per share, or 5.6%, to close at $61.05 per share on January 8, 2026.

Then, on March 6, 2026, Western Alliance Bancorp. announced that it was suing Jefferies, alleging that Jefferies’ affiliates backpedaled on previous assurances that they could pay off a large commercial loan balance.  The loans were collateralized by accounts receivable purchased from the now-collapsed First Brands. 

On this news, Jefferies’ stock price fell $5.99 per share, or 13.53%, to close at $38.29 per share on March 6, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jefferies Financial Group Inc. ("Jefferies" or the "Company") (NYSE: JEF).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Jefferies and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, The Wall Street Journal published an article entitled "Auto Supplier First Brands Files for Bankruptcy Amid Accounting Questions," reporting that "[t]he closely held company's lenders and independent board directors are now probing whether First Brands made misrepresentations in its financial reporting" and that "First Brands relied heavily on accounts-receivable-backed financing, supplying automotive products to customers on delayed payment terms and borrowing from outside investors against the billed receivables."  Then, on October 8, 2025, The Wall Street Journal further reported, in an article entitled "First Brands Bankruptcy Damage Spreads to Jefferies UBS," that Jefferies "said funds run by an asset-management unit, Point Bonita Capital, are owed around $715 million from companies that bought First Brands' parts." 

On this news, Jefferies' stock price fell $4.66 per share, or 7.88%, to close at $54.44 per share on October 8, 2025. 

The following day, Reuters disclosed that "The U.S. Department of Justice has launched an inquiry into the collapse of bankrupt auto parts maker First Brands Group" and that "[t]he Justice Department is probing the company and its dealings with creditors." 

On this news, Jefferies' stock price fell another $1.43 per share, or 2.63%, to close at $53.01 per share on October 9, 2025. 

On November 27, 2025, The Financial Times reported that the U.S. Securities and Exchange Commission is investigating Jefferies in connection with its relationship with First Brands, including whether Jefferies gave investors in its Point Bonita fund enough information about their exposure to First Brands.  Later, on January 7, 2026, The Financial Times reported that Jefferies took a $30 million loss tied to the collapse of First Brands.  

On this news, Jefferies' stock price fell $3.62 per share, or 5.6%, to close at $61.05 per share on January 8, 2026.

Then, on March 6, 2026, Western Alliance Bancorp. announced that it was suing Jefferies, alleging that Jefferies' affiliates backpedaled on previous assurances that they could pay off a large commercial loan balance.  The loans were collateralized by accounts receivable purchased from the now-collapsed First Brands. 

On this news, Jefferies' stock price fell $5.99 per share, or 13.53%, to close at $38.29 per share on March 6, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jefferies Financial Group Inc. (“Jefferies” or the “Company”) (NYSE: JEF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Jefferies and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, The Wall Street Journal published an article entitled “Auto Supplier First Brands Files for Bankruptcy Amid Accounting Questions,” reporting that “[t]he closely held company’s lenders and independent board directors are now probing whether First Brands made misrepresentations in its financial reporting” and that “First Brands relied heavily on accounts-receivable-backed financing, supplying automotive products to customers on delayed payment terms and borrowing from outside investors against the billed receivables.” Then, on October 8, 2025, The Wall Street Journal further reported, in an article entitled “First Brands Bankruptcy Damage Spreads to Jefferies UBS,” that Jefferies “said funds run by an asset-management unit, Point Bonita Capital, are owed around $715 million from companies that bought First Brands’ parts.”

On this news, Jefferies’ stock price fell $4.66 per share, or 7.88%, to close at $54.44 per share on October 8, 2025. 

The following day, Reuters disclosed that “The U.S. Department of Justice has launched an inquiry into the collapse of bankrupt auto parts maker First Brands Group” and that “[t]he Justice Department is probing the company and its dealings with creditors.” 

On this news, Jefferies’ stock price fell another $1.43 per share, or 2.63%, to close at $53.01 per share on October 9, 2025. 

On November 27, 2025, The Financial Times reported that the U.S. Securities and Exchange Commission is investigating Jefferies in connection with its relationship with First Brands, including whether Jefferies gave investors in its Point Bonita fund enough information about their exposure to First Brands. Later, on January 7, 2026, The Financial Times reported that Jefferies took a $30 million loss tied to the collapse of First Brands.

On this news, Jefferies’ stock price fell $3.62 per share, or 5.6%, to close at $61.05 per share on January 8, 2026.

Then, on March 6, 2026, Western Alliance Bancorp. announced that it was suing Jefferies, alleging that Jefferies’ affiliates backpedaled on previous assurances that they could pay off a large commercial loan balance. The loans were collateralized by accounts receivable purchased from the now-collapsed First Brands. 

On this news, Jefferies’ stock price fell $5.99 per share, or 13.53%, to close at $38.29 per share on March 6, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jefferies Financial Group Inc. (“Jefferies” or the “Company”) (NYSE: JEF).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Jefferies and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, The Wall Street Journal published an article entitled “Auto Supplier First Brands Files for Bankruptcy Amid Accounting Questions,” reporting that “[t]he closely held company’s lenders and independent board directors are now probing whether First Brands made misrepresentations in its financial reporting” and that “First Brands relied heavily on accounts-receivable-backed financing, supplying automotive products to customers on delayed payment terms and borrowing from outside investors against the billed receivables.”  Then, on October 8, 2025, The Wall Street Journal further reported, in an article entitled “First Brands Bankruptcy Damage Spreads to Jefferies UBS,” that Jefferies “said funds run by an asset-management unit, Point Bonita Capital, are owed around $715 million from companies that bought First Brands’ parts.”  

On this news, Jefferies’ stock price fell $4.66 per share, or 7.88%, to close at $54.44 per share on October 8, 2025. 

The following day, Reuters disclosed that “The U.S. Department of Justice has launched an inquiry into the collapse of bankrupt auto parts maker First Brands Group” and that “[t]he Justice Department is probing the company and its dealings with creditors.” 

On this news, Jefferies’ stock price fell another $1.43 per share, or 2.63%, to close at $53.01 per share on October 9, 2025. 

On November 27, 2025, The Financial Times reported that the U.S. Securities and Exchange Commission is investigating Jefferies in connection with its relationship with First Brands, including whether Jefferies gave investors in its Point Bonita fund enough information about their exposure to First Brands.  Later, on January 7, 2026, The Financial Times reported that Jefferies took a $30 million loss tied to the collapse of First Brands.  

On this news, Jefferies’ stock price fell $3.62 per share, or 5.6%, to close at $61.05 per share on January 8, 2026.

Then, on March 6, 2026, Western Alliance Bancorp. announced that it was suing Jefferies, alleging that Jefferies’ affiliates backpedaled on previous assurances that they could pay off a large commercial loan balance.  The loans were collateralized by accounts receivable purchased from the now-collapsed First Brands. 

On this news, Jefferies’ stock price fell $5.99 per share, or 13.53%, to close at $38.29 per share on March 6, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Posted by Defense World Staff on Apr 24th, 2026

Jefferies Financial Group Inc. (NYSE:JEF – Get Free Report) has been assigned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $58.1429.

Several analysts recently issued reports on the stock. Oppenheimer cut their price target on shares of Jefferies Financial Group from $97.00 to $74.00 and set an “outperform” rating on the stock in a report on Friday, March 13th. UBS Group decreased their price objective on shares of Jefferies Financial Group from $76.00 to $59.00 and set a “buy” rating for the company in a report on Thursday, March 12th. Zacks Research raised shares of Jefferies Financial Group from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Jefferies Financial Group in a research note on Friday, March 27th. Finally, The Goldman Sachs Group increased their price target on shares of Jefferies Financial Group from $47.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th.

Read Our Latest Research Report on Jefferies Financial Group

Key Headlines Impacting Jefferies Financial Group Here are the key news stories impacting Jefferies Financial Group this week:

Positive Sentiment: Jefferies’ research remains active and visible — analysts reiterated a Buy on Galderma, highlighting broad revenue outperformance and lower execution risk; persistent, high‑profile research helps Jefferies monetize coverage through trading and investment‑banking flow. Galderma Group AG: Broad-Based Revenue Outperformance and Lower Execution Risk Support Buy Rating Positive Sentiment: Jefferies’ coverage helped fuel a recent rally in Groww after strong Q4 results; buy recommendations from Jefferies can boost brokerage/trading volumes and underwriting opportunities if momentum continues. Groww shares rally 14% in just 3 days. Should investors buy after Q4 results? Neutral Sentiment: A slate of routine reiterations (Holds and sector notes across Europe and consumer names) suggests steady, non‑disruptive research flow rather than incremental upside or downside for JEF; this is normal recurring business. Example: Hold on XP Power. Hold Rating Maintained as Semiconductor Order Rebound Clashes with Modest Revenue Momentum Negative Sentiment: Direct negative driver: Jefferies Financial Group’s March‑quarter results missed EPS expectations ($0.70 vs. $0.89 consensus) despite revenue roughly in line — weaker EPS and modest margins weigh on near‑term sentiment and help explain the stock’s decline. Technicals (50‑day SMA below 200‑day SMA) add to short‑term pressure. Institutional Inflows and Outflows Several hedge funds have recently made changes to their positions in the company. Bison Wealth LLC bought a new stake in shares of Jefferies Financial Group in the 4th quarter valued at approximately $224,000. Arrowstreet Capital Limited Partnership bought a new position in Jefferies Financial Group during the second quarter worth $3,325,000. EverSource Wealth Advisors LLC boosted its holdings in Jefferies Financial Group by 159.3% in the second quarter. EverSource Wealth Advisors LLC now owns 892 shares of the financial services provider’s stock worth $49,000 after purchasing an additional 548 shares during the period. Amundi increased its stake in Jefferies Financial Group by 8.6% during the second quarter. Amundi now owns 226,025 shares of the financial services provider’s stock valued at $12,798,000 after purchasing an additional 17,935 shares during the last quarter. Finally, NewEdge Advisors LLC increased its stake in Jefferies Financial Group by 11.8% during the second quarter. NewEdge Advisors LLC now owns 25,970 shares of the financial services provider’s stock valued at $1,420,000 after purchasing an additional 2,751 shares during the last quarter. Institutional investors and hedge funds own 60.88% of the company’s stock.

Jefferies Financial Group Price Performance JEF stock opened at $45.69 on Tuesday. The stock’s 50 day moving average is $44.09 and its two-hundred day moving average is $53.54. Jefferies Financial Group has a 52-week low of $35.53 and a 52-week high of $71.04. The company has a market capitalization of $9.34 billion, a PE ratio of 15.44 and a beta of 1.52. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 1.87.

Jefferies Financial Group (NYSE:JEF – Get Free Report) last released its earnings results on Wednesday, March 25th. The financial services provider reported $0.70 EPS for the quarter, missing the consensus estimate of $0.89 by ($0.19). Jefferies Financial Group had a net margin of 6.61% and a return on equity of 7.83%. The business had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.02 billion. During the same quarter last year, the company posted $0.57 earnings per share. The business’s quarterly revenue was up 26.6% compared to the same quarter last year. Analysts predict that Jefferies Financial Group will post 3.79 earnings per share for the current fiscal year.

Jefferies Financial Group Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Monday, May 18th will be paid a dividend of $0.40 per share. The ex-dividend date is Monday, May 18th. This represents a $1.60 annualized dividend and a yield of 3.5%. Jefferies Financial Group’s dividend payout ratio is presently 54.05%.

About Jefferies Financial Group (Get Free Report)

Jefferies Financial Group Inc is a diversified financial services company that provides a range of investment banking, capital markets and asset management services to corporations, governments and institutional investors worldwide. Through its core platform, Jefferies offers advisory services for mergers and acquisitions, debt and equity underwriting, restructuring and recapitalization. The firm also operates a global sales and trading business covering equities, fixed income and foreign exchange products, complemented by equity research and macroeconomic analysis.

In addition to its capital markets franchise, Jefferies maintains a growing asset management division that delivers customized investment solutions across public and private markets.

Featured Stories Five stocks we like better than Jefferies Financial Group

Receive News & Ratings for Jefferies Financial Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jefferies Financial Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECwm LLC Buys 10,699 Shares of SPDR S&P Biotech ETF $XBI

NEXT HEADLINE »Carpenter Technology Corporation (NYSE:CRS) Receives $403.11 Average Price Target from Analysts

Posted by Defense World Staff on Apr 27th, 2026

Consumer Portfolio Services (NASDAQ:CPSS – Get Free Report) and Jefferies Financial Group (NYSE:JEF – Get Free Report) are both finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings This is a breakdown of current ratings for Consumer Portfolio Services and Jefferies Financial Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Consumer Portfolio Services 1 0 0 0 1.00 Jefferies Financial Group 0 4 3 0 2.43 Jefferies Financial Group has a consensus price target of $58.14, suggesting a potential upside of 22.55%. Given Jefferies Financial Group’s stronger consensus rating and higher probable upside, analysts plainly believe Jefferies Financial Group is more favorable than Consumer Portfolio Services.

Profitability This table compares Consumer Portfolio Services and Jefferies Financial Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Consumer Portfolio Services 4.45% 6.34% 0.51% Jefferies Financial Group 6.61% 7.83% 1.15% Institutional and Insider Ownership 47.6% of Consumer Portfolio Services shares are held by institutional investors. Comparatively, 60.9% of Jefferies Financial Group shares are held by institutional investors. 63.7% of Consumer Portfolio Services shares are held by company insiders. Comparatively, 19.9% of Jefferies Financial Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk Consumer Portfolio Services has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Jefferies Financial Group has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

Earnings & Valuation This table compares Consumer Portfolio Services and Jefferies Financial Group”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Consumer Portfolio Services $434.47 million 0.42 $19.33 million $0.80 10.59 Jefferies Financial Group $10.82 billion 0.90 $710.47 million $2.96 16.03 Jefferies Financial Group has higher revenue and earnings than Consumer Portfolio Services. Consumer Portfolio Services is trading at a lower price-to-earnings ratio than Jefferies Financial Group, indicating that it is currently the more affordable of the two stocks.

Summary Jefferies Financial Group beats Consumer Portfolio Services on 13 of the 14 factors compared between the two stocks.

About Consumer Portfolio Services (Get Free Report)

Consumer Portfolio Services, Inc. operates as a specialty finance company in the United States. It is involved in the purchase and service of retail automobile contracts originated by franchised automobile dealers and select independent dealers in the sale of new and used automobiles, light trucks, and passenger vans. The company, through its automobile contract purchases, offers indirect financing to the customers of dealers with limited credit histories or past credit problems. It also serves as an alternative source of financing for dealers, facilitating sales to customers who are not able to obtain financing from commercial banks, credit unions, and the captive finance companies. In addition, the company acquires installment purchase contracts in merger and acquisition transactions; purchases immaterial amounts of vehicle purchase money loans from non-affiliated lenders. It services its automobile contracts through its branches in California, Nevada, Virginia, Florida, and Illinois. The company was incorporated in 1991 and is based in Las Vegas, Nevada.

About Jefferies Financial Group (Get Free Report)

Jefferies Financial Group Inc. operates as an investment banking and capital markets firm in the Americas, Europe, the Middle East, and the Asia-Pacific. The company operates in two segments, Investment Banking and Capital Markets, and Asset Management. It provides investment banking, advisory services with respect to mergers or acquisitions, debt financing, restructurings or recapitalizations, and private capital advisory transactions; underwriting and placement services related to corporate debt, municipal bonds, mortgage-backed and asset-backed securities, equity and equity-linked securities, and loan syndication services; and corporate lending services. The company also offers financing, securities lending, and other prime brokerage services; equities research, sales, and trading services; wealth management services; and online foreign exchange trading services. In addition, it provides investment grade distressed debt securities, U.S. and European government and agency securities, municipal bonds, leveraged loans, emerging markets debt, and interest rate and credit index derivative products; and manages and offers services to a diverse group of alternative asset management platforms across a spectrum of investment strategies and asset classes. The company was formerly known as Leucadia National Corporation and changed its name to Jefferies Financial Group Inc. in May 2018. Jefferies Financial Group Inc. was founded in 1962 and is headquartered in New York, New York.

Receive News & Ratings for Consumer Portfolio Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consumer Portfolio Services and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBest Robotics Stocks To Research – April 25th

NEXT HEADLINE »Valvoline (NYSE:VVV) Given Average Rating of “Moderate Buy” by Brokerages

📌 Top story -- scroll down for more updates

Donuts and Wings and an IPO 5:24 pm

It’s Friday, so treat yourself! Inspire Brands, the private empire behind Dunkin’, Arby’s, Buffalo Wild Wings, Sonic Drive-In, Baskin Robbins, and Jimmy John’s, just confidentially filed for an IPO. Backer Roark Capital wants a $20 billion valuation, which would rank this among the biggest restaurant offerings ever.

33,300 locations, $33.4B in sales: That looks like a small nation that runs on coffee and chicken wings. They’re not alone: Jersey Mike’s also filed last month. Everyone wants a slice of the public markets right now, even if the IPO window is only half-open. How Big Is Inspire Brands?

🍩 Restaurants

33,300+

👨‍🍳 Team members

650,000

🤝 Franchisees

2,700+

🌍 Global markets

57

📱 U.S. digital sales

$11B+

Source: inspirebrands.com/about-us/

Micron Recovers as Memory Demand Holds 4:20 pm — MU +15.49% today

That was quite a 24-hour stretch for Micron (MU 1.02%)! Shares tumbled 3% Thursday after Bernstein raised the alarm on the computer memory spot market, then rocketed 9% Friday morning, with Bernstein once again pulling the strings, to end the day up 15.5%. (Leave it to Wall Street...) The worry is that DRAM and NAND prices have gotten so hot that some buyers are being priced out, which could pump the brakes on gains heading into Q2 2026. But here’s the twist. April DRAM prices surged 57% versus Q1 averages, and NAND jumped 65–70%. The buyers who can afford memory are still buying — aggressively — and that’s keeping the bull case very much alive.

Don’t panic about Q2: Analysts still expect Micron to earn about $19/share in the May quarter on $33.5 billion in revenue, a jaw-dropping 260% sales increase year over year. That price target, though: Bernstein’s buy rating hasn’t budged but it's sitting on a $510 target while Micron trades well above it — an awkward position that suggests a revision is coming, and probably soon. Foolish investors would do well to tune out the noise. After all, Micron is among the highest-scoring companies in both the Hidden Gems primary and Rule Breakers primary Moneyball databases.

Today's Change

(

-1.02

%) $

-10.15

Current Price

$

985.72

Closing Bell 4:06 pm

The S&P 500 and Nasdaq hit all-time intraday highs Friday after April’s jobs report showed nonfarm payrolls rising 177,000 — that was well above the 130,000 economists expected — while the unemployment rate held at 4.2%. The Nasdaq gained 4.5% over the past 5 days, powered by AI-driven tech earnings. Tempering the mood: a skirmish between U.S. and Iranian forces in the Strait of Hormuz sent oil prices up 1% to around $95 per barrel, though President Trump called the exchange "just a love tap" and Secretary of State Rubio said a ceasefire response from Iran was expected Friday.

Burry’s dot-com warning: Michael Burry says the market "feels like the last months of the 1999–2000 bubble," pointing to stocks rising simply because they’ve been rising — on a "two-letter thesis" (AI) everyone thinks they understand. Memory stocks on fire: Micron Technology (MU 1.02%) and Sandisk (SNDK +5.24%) each surged about 13% Friday and are up 35% and 27% respectively on the week, as the Philadelphia Semiconductor Index climbs 10%+ and notches 65% gains in 2026. Toast Drops 15% Despite AI Wins 3:50 pm — TOST -14.21%

By Tim Beyers
Team Rule Breakers

Shares of Toast (TOST +0.53%) are down close to 15% today on what appears to be concern about input costs -- particularly hardware costs -- as a result of tariffs impacting the supply chain. Macro concerns may also be in place. And yet Toast had a decent quarter. Already, 40,000 locations use the Toast IQ AI chatbot and those using the new Toast IQ Grow agent are seeing a meaningful uptick in order size. I’ll report more after carefully listening to the conference call.

Today's Change

(

0.53

%) $

0.13

Current Price

$

24.82

HubSpot Drops 20% on Soft Guidance 3:27 pm — HUBS -19.64%

HubSpot (HUBS +0.77%) got absolutely walloped Friday — down 20% — despite actually beating Q1 estimates. Revenue climbed 23% to $881 million, and adjusted EPS of $2.73 cleared the bar handily. What went wrong? Q2 revenue guidance of $897–$898 million landed just shy of the $902 million Wall Street wanted, and that was enough to send investors scrambling for the exits.

The agentic growing pains are real: HubSpot slashed prices on its Customer Agent and Prospecting Agent products in April, threw in 28-day free trials, and then discovered its own sales team needed retraining on the new usage-based plans. It was a perfect storm for a soft quarter start. Bargain or value trap? At just 16.0x this year’s earnings estimates, HUBS looks genuinely cheap. But until software companies prove they can thrive — not just survive — in the agentic AI era, the "SaaS-pocalypse" discount is likely here to stay. Metric (GAAP unless noted)Q1 2026Q1 2025Y/Y ChangeEPS (Non-GAAP)$2.72$1.78+52.8%Revenue (millions)$881.0$714.1+23.4%Operating Margin (Non-GAAP)17.8%14.0%+3.8 ppFree Cash Flow (Non-GAAP, millions)$153.7$122.3+25.6%Customers (Non-GAAP)299,458258,147+16.0% Baby Boom Fuels Progyny’s Rally 2:46 pm — PGNY +20.41%

By Alicia Alfiere
Team Rule Breakers

Progyny’s (PGNY +3.74%) stock is up today, partly because of the conservative guidance issued during its fourth-quarter earnings call. Back in March, Progyny projected that benefit usage could slip to the lower end of its historical range. That conservative guidance likely caused Progyny’s share price to decline after its fourth-quarter results were released.

The company reported first-quarter earnings and, instead of historically low benefit utilization, said member engagement came in at the higher end of expectations.

Nelnet’s Growth Continues 2:26 pm — NNI -15.07%

By Buck Hartzell

All divisions of Nelnet (NNI +1.35%) grew YoY. The biggest driver of growth is their acquisition of Klarna’s (KLAR 1.04%) BNPL loans. That balance reached $766.2 million at quarter end. Their provision for loan losses was $48.5 million vs $13.0 million in Q1 2025. This was entirely due to portfolio growth. Their bank saw net loan and interest income grow 43.5% YoY to $17.8 million. Loan Servicing grew revenues 5.8% to $128.8 million. Education Technology and Payments grew revenues 4.8% YoY to $154.4 million. Nelnet still has two very large assets in ALLO Communications and Hudl that I believe are undervalued on their balance sheet. The stock is still a buy.

Today's Change

(

1.35

%) $

1.73

Current Price

$

130.30

Amazon Data Center Overheats 1:10 pm -- AMZN +0.8%

Amazon (AMZN 1.24%) Web Services is battling a "thermal issue" at a Northern Virginia data center that has crippled major trading and betting platforms. Starting Thursday night, the overheating in a primary US-East-1 availability zone triggered server impairments for Coinbase Global (COIN 0.41%) and Flutter Entertainment's (FLUT 0.14%) FanDuel. While Coinbase reported core services are resolving, FanDuel users faced extended lockouts, preventing crucial mid-game bet cash-outs. AWS, which controls a third of the cloud market, expects a full recovery to take several hours as technicians bring supplemental cooling capacity online to rescue the affected hardware.

The Cost of Centralization: This single-zone failure highlights the systemic risk for fintech firms reliant on AWS, as even localized hardware heat can disconnect millions from global markets. Infrastructure Fragility: The reliance on EC2 virtual servers means that until the physical Virginia facility cools down, digital platforms remain vulnerable to intermittent "instance impairments." Today's Lunchtime News 1:05 pm -- PGNY +17.5%

Progyny (PGNY +3.74%) posted higher first-quarter revenue and profit while expanding its client base and completing a $200 million share repurchase program, signaling continued momentum despite the loss of a previously disclosed large client. Revenue rose 1.4% year over year to $328.5 million, or 12.2% excluding the lapsed contract.

Operational highlights: Net income jumped to $24.2 million, or $0.29 per diluted share, from $15.1 million a year earlier, while gross margin expanded to 25.3% from 23.4% on operational efficiencies and lower stock-based comp. Fertility benefit services revenue rose 1.5% to $209.4 million, and the company served 595 fertility and family building clients, up from 532 a year earlier. Capital return push: Progyny repurchased more than 5.5 million shares for $116.4 million during the quarter, completing its $200 million authorization. The board is currently evaluating a new repurchase plan. CEO Pete Anevski said the early selling season is pacing ahead of last year, with new pipeline build "substantially favorable" versus a year ago.

Today's Change

(

3.74

%) $

0.96

Current Price

$

26.61

MercadoLibre's Revenue Surges 49% 12:20 pm

By Buck Hartzell

MercadoLibre's (MELI 1.25%) margins shrank as they invested in future growth. Credit expansion, improved logistics, first party sales, cross border trade and free shipping are all working well.

Revenue + 49% YoY (46% FXN) to $8.8 B USD (fastest growth since Q2 2022) Income from ops -19.9% to $611 M (6.9% margin vs 12.9% in Q1 25) Net income -15.5% to $417 M (4.7% margin vs 8.3% in Q1 25) TPV + 50% YoY (55% FXN) to $87.2 B Credit portfolio + 87% YoY to $14.6 B Issued 2.7 M credit cards in Q1 26. Credit growth requires reserving, which hurts near term margins. The stock remains attractive for patient capital.

Today's Change

(

-1.25

%) $

-20.12

Current Price

$

1589.88

Gas Prices Sink Sentiment to New Low 11:25 am

Consumer sentiment plummeted to a preliminary reading of 48.2 in May, marking a fresh record low as the Iran war continues to drive energy costs higher. Despite a strong labor report, the University of Michigan survey revealed that one-third of respondents blame surging gas prices — now averaging $4.54 nationally — for their deteriorating outlook. While retail giants like Walmart (WMT +0.44%) and Amazon (AMZN 1.24%) have remained resilient, the 9% drop in current conditions suggests major purchases are being shelved. Sentiment is unlikely to recover until supply disruptions resolve, though stock indexes stayed positive as long-term inflation expectations eased slightly to 3.4%.

The Double-Whammy Effect: Beyond the pump, another third of consumers cited aggressive tariffs as a primary headwind, creating a challenging environment for import-heavy companies like Target (TGT +1.95%). Inflationary Silver Lining: While current attitudes are grim, the one-year inflation projection dipped to 4.5%, offering the Federal Reserve a slim hope that price expectations are not becoming permanently unanchored.

The High Cost of Scaling AI 10:25 am

The AI infrastructure race is becoming a high-stakes cash-flow test for Alphabet (GOOG +0.44%), Microsoft (MSFT +0.11%), Amazon (AMZN 1.24%), and Meta Platforms (META 0.14%). Capital expenditures for data centers and chips are consuming an increasingly large share of operating cash, with Amazon spending nearly everything it generates on build-outs. Alphabet is the most striking example of this tension; its forward price-to-free-cash-flow multiple has soared above 200x. While these "hyperscalers" can afford the massive investment, the market is closely watching for when this capital-intensive "backbone" starts yielding clear bottom-line payoffs as free cash flow gets squeezed.

The 100% Threshold: If capex exceeds operating cash, these giants must look beyond daily profits to fund growth, a pivot that historically triggers investor anxiety. Valuation Disconnect: Alphabet’s surging multiple suggests investors are pricing in future AI dominance while simultaneously ignoring the shrinking pile of cash that survives the build-out. Opening Bell 9:35 am

Markets are climbing this Friday as a robust jobs report and resilient tech earnings override geopolitical friction. Nonfarm payrolls added 115,000 positions in April, shattering the 55,000 estimate, while the unemployment rate held steady at 4.3%. Chipmakers are providing the muscle, with Qualcomm (QCOM +4.32%) up 6% and Micron Technology (MU 1.02%) rising 4%. Despite a brief exchange of fire in the Strait of Hormuz, which President Trump characterized as a "love tap," markets remain optimistic. Investors are closely watching for Iran's formal response to a peace proposal as the S&P 500 continues to flirt with all-time highs.

Broad-Based Earnings Power: Analysts expect 20% year-over-year earnings growth to persist through 2026, suggesting the current market momentum has significant fundamental support beyond just a few tech giants. Energy Market Tension: Crude prices hover near $95 as the U.S. Navy destroyers intercepted attacks, though the continued ceasefire suggests traders are pricing in a diplomatic resolution rather than a full-scale oil supply shock. Market indexes

S&P 500

0.48%

Nasdaq

0.66%

Dow

0.36%

Trade Desk's Real Risk Is the Publicis Standoff 9:15 am -- TTD -13.11% in pre-market trading

By Sanmeet Deo
Team Rule Breakers

It seems the most pressing concern coming out of The Trade Desk's (TTD +2.06%) Q1 2026 earnings is not the macro nor the EPS miss but whether the Publicis situation represents an isolated negotiating dispute or the beginning of a broader agency pushback against TTD's pricing and transparency practices.

Omnicom's subsequent audit found no issues, which suggests the Publicis allegations may be overstated. But the market does not trade on what Omnicom found. It trades on uncertainty, and the uncertainty here is significant. Publicis manages enormous ad budgets for global brands. If their advisory against TTD sticks with even a portion of their clients, the revenue impact in Q2 and Q3 could be material, and TTD's guidance would be giving no credit to that risk.

The secondary concern is margin trajectory. A full-year target of at least 40% adjusted EBITDA margin requires a dramatic improvement from the 30% reported in Q1. That ramp requires either a meaningful revenue acceleration in the back half of the year or aggressive cost containment. The call gave investors no clear picture of which lever management is pulling.

The bull case remains intact in the long-term, the open Internet thesis, retail media, AI search, objectivity as competitive advantage. Jeff Green's $150 million personal stock purchase is not nothing. But the near-term is genuinely cloudy, and the call did more to validate investor anxiety than to resolve it.

Today's Change

(

2.06

%) $

0.39

Current Price

$

19.29

U.S. Hiring Surges Past Expectations 9:15 am

The U.S. labor market demonstrated surprising resilience in April, adding 115,000 jobs--nearly doubling economist forecasts of 65,000. While the tech-heavy information sector continues to contract, essential services like healthcare and logistics are propping up the S&P 500. Wage growth moderated to a 3.6% annual clip, providing a "Goldilocks" scenario for the Federal Reserve: strong enough to prevent a recession, but cool enough to avoid an inflationary spiral. This stability likely cements a "higher-for-longer" interest rate path, favoring companies with robust cash flows over speculative growth names.

Lime's IPO Filing Signals Thaw in IPO Market 8:00am

Micromobility pioneer Lime, officially incorporated as Neutron Holdings, has filed for an initial public offering to list on the Nasdaq under the ticker symbol "LIME." The start-up arrives at the public gates with significant institutional backing, most notably from Uber Technologies (UBER 1.01%), and a narrative centered on robust revenue expansion and a surging global user base. While the filing remains "placeholder" in nature--omitting specific pricing terms and valuation targets--the heavy-hitting underwriting team led by Goldman Sachs (GS +2.62%) and JPMorgan Chase (JPM +2.28%) suggests a high-conviction push to capitalize on the recent thaw in the IPO market.

Strategic Ecosystem Value: As a key partner in the Uber app ecosystem, Lime's public performance will be a critical litmus test for the long-term viability of the rental scooter and e-bike business model. Wall Street Heavyweights: The inclusion of top-tier bookrunners like Jefferies (JEF +3.35%) and Evercore (EVR +0.64%) indicates that institutional appetite for late-stage venture success stories is returning to the transportation sector. This Morning's Breakfast News 7:30 am -- NET -17.75% in pre-market trading

Cloudflare (NET +0.23%) fell over 18% ahead of the opening bell as investors see the company belatedly playing catch-up on AI, with management noting it's "the biggest tailwind we've ever seen," along with quarterly results showing a 4.67% fall in gross profit margins from the prior-year period.

"Cloudflare's usage of AI has increased by more than 600% in the last three months alone": 1,100 staff are being cut, with an email sent to staff saying management "have to be intentional in how we architect our company for the agentic AI era," with the job cuts representing 20% of the current workforce. News overshadows strong set of results: Despite the fall in gross margin, revenue rose by 34% versus the same period last year, with the outlook for full-year fiscal 2026 revenue and earnings raised.

ICYMI: Thursday's Scoreboard 6:30 am -- COST unchanged in pre-market trading

Costco (COST +0.67%) was the subject of the latest Scoreboard video.

Rocket Lab's Best Quarter Is the Drama-Free One 6:00 am -- RKLB +6.83% in pre-market trading

By Lou Whiteman
Team Hidden Gems

Rocket Lab (RKLB 10.91%) beat expectations for the quarter, but the real story of the earnings report was how little drama there was about the quarter.

The company generated $200 million in revenue in the quarter and posted a $12 million EBITDA loss, better than Wall Street's $190 million and a loss of $26 million expectation. But note that the company had guided for $185 million to $200 million in revenue, and the EBITDA beat was largely because of accounting: Rocket Lab benefited from a reversal of some 2025 bonus compensation accruals.

Rocket Lab needs to be viewed as a long-term growth story, not a quarter-to-quarter standout. And the company's forecast for the future, though not surprising, was encouraging. The company grew its backlog by 20% since last quarter thanks to strong bookings in its launch business.

Today's Change

(

-10.91

%) $

-12.52

Current Price

$

102.26

TSMC's AI Demand Drives April Revenue Higher 5:15 am -- TSM +0.63% in pre-market trading

TSMC (TSM +0.46%) reported a robust 17.5% year-over-year revenue increase for April, totaling NT$410.73 billion ($13.08 billion), as the global appetite for advanced AI hardware remains insatiable. While monthly sales dipped a marginal 1.1% from March, the year-to-date trajectory is formidable, with revenue up nearly 30% through the first four months of 2026. The world's leading foundry is successfully navigating a complex macro environment, leveraging its dominance in 3nm and 5nm nodes to support "Magnificent Seven" clients like Nvidia (NVDA +0.15%) and Apple (AAPL 1.52%). Management's bullish Q2 guidance of up to $40.2 billion suggests that the bottleneck for growth remains production capacity rather than a lack of orders.

Aggressive Capex Expansion: To meet "extremely strong" demand, the company has raised its 2026 capital expenditure target to a range of $52 billion to $56 billion, focusing on advanced packaging and new global fabs. Geopolitical Balancing Act: Despite tightening U.S. technology restrictions on high-end silicon, TSMC's record-high margins of 66.2% prove its specialized manufacturing moat currently outweighs the risk of regional trade friction.

Today's Change

(

0.46

%) $

1.94

Current Price

$

423.01

Top of the Morning 5:00 am -- SRAD +0.88% in pre-market trading

By Morning Show host Jim Mueller, CFA
Team Rule Breakers

What should you do if you're the CEO of a company when a short attack article comes out about your company?

If you're smart, very little. At most, comment on any errors of fact, answer analyst questions, and then shut up.

That's what Carsten Koerl, CEO of Sportradar (SRAD 5.72%), has done.

A bit over two weeks ago, Muddy Waters and Calisto Research put out nearly identical short reports on the company claiming, among other things, that the company should be unprofitable because it was purposefully doing business with criminal enterprises. Evidence given was an interaction with a sales rep and finding evidence of Sportradar's code on various illegal gambling websites.

Shares fell over 20% that day. Good for Muddy Waters, I guess.

In reply, the company moved up its earnings release and did nothing else until the new release date. Then, on the day of earnings, they filed with the SEC a document explaining that there were three ways for their code to be found on various sites, only one of which was legitimate. Further, the way Muddy Waters detected the code couldn't distinguish among the three.

During the conference call Koerl also answered questions posed by analysts about various points raised by Muddy Waters. For example, he said that the sales rep was quite young (as in inexperienced) and that talk is talk until due diligence has been performed. He strongly implied that such due diligence would have not led anywhere if the Muddy Waters reps were legitimate instead of trying to entrap the rep.

He answered a few other questions, but then he did a smart thing. He shut up.

4:30 am -- ABNB -0.98% in pre-market trading

By Morning Show host Alicia Alfiere
Team Rule Breakers

Airbnb (ABNB +1.08%) reported that gross booking value, which is the value of bookings on the booking platform, grew 19% to total $2.9 billion in the first quarter. That's impressive, but what's more fascinating is that the company's new "Reserve Now, Pay Later" bookings drove roughly 20% of global gross booking value. This new feature has changed how guests can book and Airbnb reports that the increased flexibility has caused long lead times and travelers booking pricier accommodations.

And there were other signs of a platform that continues to grow-like an increase in first time bookers. The growth in these new-to-Airbnb travelers grew 10% in the first quarter-which is the highest rate seen since early 2022. Additionally, this new Airbnb-er expansion is driven by younger customers and travelers who live in Airbnb's expansion markets, like Brazil, Japan, and India.

Today's Change

(

1.08

%) $

1.41

Current Price

$

132.28

Before the Opening Bell 4:45 am

U.S. stock futures advanced early Friday as optimism over a potential diplomatic resolution to the U.S.-Iran conflict outweighed Thursday's slight retreat from record highs. Despite the Dow's 314-point slide yesterday, all three major benchmarks remain on track for a winning week, buoyed by a resilient tech earnings season. The Nasdaq Composite leads the charge with a projected 2.8% weekly gain, while the S&P 500 and Dow Jones Industrial Averagehave risen 1.5% and 0.2%, respectively. All eyes now pivot to the April nonfarm payrolls report, which will serve as a critical health check for the economy amid shifting geopolitical undercurrents.

JPMorgan Chase is an advertising partner of Motley Fool Money. This article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. Alicia Alfiere, MBA has positions in Alphabet, Amazon, Apple, Costco Wholesale, Microsoft, Nelnet, and Progyny. Buck Hartzell has positions in Alphabet, Apple, JPMorgan Chase, MercadoLibre, Microsoft, and Nelnet. Jim Mueller, CFA has positions in Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nelnet, Nvidia, Sportradar Group, Toast, and Walmart and has the following options: long January 2027 $215 calls on Amazon, long January 2028 $230 calls on Amazon, long January 2028 $7.50 calls on Sportradar Group, short January 2027 $225 calls on Amazon, short January 2028 $240 calls on Amazon, short June 2026 $210 puts on Amazon, short June 2026 $31 calls on Toast, and short May 2026 $22.50 calls on Sportradar Group. Lou Whiteman has positions in Cloudflare, MercadoLibre, Nelnet, Rocket Lab, Taiwan Semiconductor Manufacturing, The Trade Desk, and Walmart. Sanmeet Deo, CFA has positions in Alphabet, Amazon, The Trade Desk, Toast, and Walmart. Tim Beyers has positions in Alphabet, Amazon, Apple, HubSpot, MercadoLibre, Progyny, Taiwan Semiconductor Manufacturing, and Toast. The Motley Fool has positions in and recommends Airbnb, Alphabet, Amazon, Apple, Cloudflare, Costco Wholesale, Evercore, Goldman Sachs Group, HubSpot, JPMorgan Chase, Jefferies Financial Group, Klarna Group, MercadoLibre, Meta Platforms, Micron Technology, Microsoft, Nelnet, Nvidia, Progyny, Qualcomm, Rocket Lab, Sportradar Group, Taiwan Semiconductor Manufacturing, Target, The Trade Desk, Toast, Uber Technologies, and Walmart. The Motley Fool recommends Coinbase Global and Flutter Entertainment Plc and recommends the following options: short May 2026 $22.50 calls on Sportradar Group. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Jefferies Financial Group Inc. (NYSE: JEF) focused on whether Jefferies as well as certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in the Jefferies investigation or if you are a Jefferies investor who suffered a loss and would like to learn more, you can provide your information here:

https://www.rgrdlaw.com/cases-jefferies-financial-group-inc-investigation-jef.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

THE COMPANY: Jefferies Financial Group Inc. is a global full-service investment banking and capital markets firm.  Under the Leucadia Asset Management ("LAM") umbrella, Jefferies manages and provides services to a diverse group of alternative asset management platforms.  Point Bonita Capital is a division of LAM.

THE REVELATION: On September 29, 2025, The Wall Street Journal published an article entitled "Auto Supplier First Brands Files for Bankruptcy Amid Accounting Questions," reporting that "[t]he closely held company's lenders and independent board directors are now probing whether First Brands made misrepresentations in its financial reporting" and that "First Brands relied heavily on accounts-receivable-backed financing, supplying automotive products to customers on delayed payment terms and borrowing from outside investors against the billed receivables."

On October 8, 2025, The Wall Street Journal further reported, in an article entitled "First Brands Bankruptcy Damage Spreads to Jefferies UBS," that Jefferies "said funds run by an asset-management unit, Point Bonita Capital, are owed around $715 million from companies that bought First Brands' parts."  The following day, Reuters disclosed that "The U.S. Department of Justice has launched an inquiry into the collapse of bankrupt auto parts maker First Brands Group" and that "[t]he Justice Department is probing the company and its dealings with creditors."

On October 12, 2025, The Wall Street Journal published another article entitled "Behind the Collapse of an Auto-Parts Giant: $2 Billion Hole and Mysterious CEO," reporting that First Brands' now former CEO "was working on an effort to refinance the nearly $6 billion of corporate loans with the help of Jefferies" and that "[t]he pitch to prospective lenders didn't mention the billions of dollars of off -balance-sheet debt, people familiar with the matter said."

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading firms representing investors in securities fraud and shareholder litigation.  Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors.  In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five firms combined, according to ISS.  With 200 attorneys in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.  
Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP

Michael Albert

Ken Dolitsky

655 W. Broadway, Suite 1900, San Diego, CA  92101 

800/851-7783

[email protected]

SOURCE Robbins Geller Rudman & Dowd LLP

San Diego, California--(Newsfile Corp. - June 8, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Jefferies Financial Group Inc. (NYSE: JEF) focused on whether Jefferies as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in the Jefferies investigation or if you are a Jefferies investor who suffered a loss and would like to learn more, you can provide your information here:

https://www.rgrdlaw.com/cases-jefferies-financial-group-inc-investigation-jef.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

THE COMPANY: Jefferies Financial Group Inc. is a global full-service investment banking and capital markets firm. Under the Leucadia Asset Management ("LAM") umbrella, Jefferies manages and provides services to a diverse group of alternative asset management platforms. Point Bonita Capital is a division of LAM.

THE REVELATION: On September 29, 2025, The Wall Street Journal published an article entitled "Auto Supplier First Brands Files for Bankruptcy Amid Accounting Questions," reporting that "[t]he closely held company's lenders and independent board directors are now probing whether First Brands made misrepresentations in its financial reporting" and that "First Brands relied heavily on accounts-receivable-backed financing, supplying automotive products to customers on delayed payment terms and borrowing from outside investors against the billed receivables."

On October 8, 2025, The Wall Street Journal further reported, in an article entitled "First Brands Bankruptcy Damage Spreads to Jefferies UBS," that Jefferies "said funds run by an asset-management unit, Point Bonita Capital, are owed around $715 million from companies that bought First Brands' parts." The following day, Reuters disclosed that "The U.S. Department of Justice has launched an inquiry into the collapse of bankrupt auto parts maker First Brands Group" and that "[t]he Justice Department is probing the company and its dealings with creditors."

On October 12, 2025, The Wall Street Journal published another article entitled "Behind the Collapse of an Auto-Parts Giant: $2 Billion Hole and Mysterious CEO," reporting that First Brands' now former CEO "was working on an effort to refinance the nearly $6 billion of corporate loans with the help of Jefferies" and that "[t]he pitch to prospective lenders didn't mention the billions of dollars of off -balance-sheet debt, people familiar with the matter said."

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five firms combined, according to ISS. With 200 attorneys in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
Robbins Geller Rudman & Dowd LLP
Michael Albert
Ken Dolitsky
655 W. Broadway, Suite 1900, San Diego, CA 92101
800/851-7783
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300436

Source: Robbins Geller Rudman & Dowd LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Jefferies Financial Group Inc. (NYSE: JEF) focused on whether Jefferies as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in the Jefferies investigation or if you are a Jefferies investor who suffered a loss and would like to learn more, you can provide your information here:

https://www.rgrdlaw.com/cases-jefferies-financial-group-inc-investigation-jef.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

THE COMPANY: Jefferies Financial Group Inc. is a global full-service investment banking and capital markets firm.  Under the Leucadia Asset Management ("LAM") umbrella, Jefferies manages and provides services to a diverse group of alternative asset management platforms.  Point Bonita Capital is a division of LAM.

THE REVELATION: On September 29, 2025, The Wall Street Journal published an article entitled "Auto Supplier First Brands Files for Bankruptcy Amid Accounting Questions," reporting that "[t]he closely held company's lenders and independent board directors are now probing whether First Brands made misrepresentations in its financial reporting" and that "First Brands relied heavily on accounts-receivable-backed financing, supplying automotive products to customers on delayed payment terms and borrowing from outside investors against the billed receivables."

On October 8, 2025, The Wall Street Journal further reported, in an article entitled "First Brands Bankruptcy Damage Spreads to Jefferies UBS," that Jefferies "said funds run by an asset-management unit, Point Bonita Capital, are owed around $715 million from companies that bought First Brands' parts."  The following day, Reuters disclosed that "The U.S. Department of Justice has launched an inquiry into the collapse of bankrupt auto parts maker First Brands Group" and that "[t]he Justice Department is probing the company and its dealings with creditors."

On October 12, 2025, The Wall Street Journal published another article entitled "Behind the Collapse of an Auto-Parts Giant: $2 Billion Hole and Mysterious CEO," reporting that First Brands' now former CEO "was working on an effort to refinance the nearly $6 billion of corporate loans with the help of Jefferies" and that "[t]he pitch to prospective lenders didn't mention the billions of dollars of off -balance-sheet debt, people familiar with the matter said."

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading firms representing investors in securities fraud and shareholder litigation.  Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors.  In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five firms combined, according to ISS.  With 200 attorneys in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.  
Services may be performed by attorneys in any of our offices. 

Contact:

          Robbins Geller Rudman & Dowd LLP

          Michael Albert

           Ken Dolitsky

          655 W. Broadway, Suite 1900, San Diego, CA  92101 

          800/851-7783

          [email protected]

SOURCE Robbins Geller Rudman & Dowd LLP

Louisiana-Pacific (LPX - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this home construction supplier have returned -0.9% over the past month versus the Zacks S&P 500 composite's +9.7% change. The Zacks Building Products - Wood industry, to which Louisiana-Pacific belongs, has gained 3.9% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Louisiana-Pacific is expected to post earnings of $0.09 per share for the current quarter, representing a year-over-year change of -92.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +18.1%.

The consensus earnings estimate of $2.7 for the current fiscal year indicates a year-over-year change of +1.9%. This estimate has changed -3.2% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $4.72 indicates a change of +74.9% from what Louisiana-Pacific is expected to report a year ago. Over the past month, the estimate has changed -1%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Louisiana-Pacific is rated Zacks Rank #4 (Sell).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Louisiana-Pacific, the consensus sales estimate for the current quarter of $572.45 million indicates a year-over-year change of -20.9%. For the current and next fiscal years, $2.69 billion and $3.12 billion estimates indicate -0.7% and +16% changes, respectively.

Last Reported Results and Surprise HistoryLouisiana-Pacific reported revenues of $567 million in the last reported quarter, representing a year-over-year change of -16.7%. EPS of $0.03 for the same period compares with $1.03 a year ago.

Compared to the Zacks Consensus Estimate of $603.3 million, the reported revenues represent a surprise of -6.02%. The EPS surprise was +150%.

Over the last four quarters, Louisiana-Pacific surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Louisiana-Pacific is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Louisiana-Pacific. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.